CD4 and neoplasm: To assess the capacity of our mCAR-Vβ2 T cells to target malignant T cells in vivo, we generated a patient-derived xenograft (PDX) model in NSG mice (Fig. 2a) populated with total CD4 T cells from a Vβ2+ leukemic PTCL patient, or with tumor line Jurkat-TRBV20-1 (Vβ2+) cells.